8-K: AIM ImmunoTech Adjusts Warrants to Floor Price

AIM ImmunoTech Inc. announced adjustments to its Class E and F common stock purchase warrants, reducing the exercise price to $1.439 per share and increasing the number of outstanding warrants to 5,561,125 following a stock dividend.

Summary

• AIM ImmunoTech Inc. issued notices regarding changes and modifications to its Class E and Class F Common Stock Purchase Warrants.
• On January 13, 2026, the company distributed a dividend of one share of common stock for every 1,000 shares outstanding as of January 9, 2026, and for every outstanding option or warrant with stock dividend rights.
• This dividend was classified as a "Share Combination Event" under Section 3(g) of the Warrants.
• Due to the lowest Volume Weighted Average Price (VWAP) during the evaluation period being below the adjusted floor price of $1.439, the exercise price of the warrants has been reduced to $1.439 per share.
• The number of outstanding warrants has been increased to 5,561,125.
• Section 3(g) of the warrants cannot be triggered again for further reductions as the exercise price has reached the floor.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the warrant exercise price being reduced to its floor, implying recent low trading prices for the underlying common stock. While the adjustment is procedural, the underlying market condition that triggered it is unfavorable. The forward-looking statements also emphasize significant risks and uncertainties regarding Ampligen's development.

Positives

• The warrant adjustments were made in accordance with the pre-defined terms of the warrants, demonstrating adherence to corporate governance.

Negatives

• The Volume Weighted Average Price (VWAP) during the evaluation period was below the adjusted floor price of $1.439, indicating recent low trading prices for the common stock.
• The exercise price of the warrants has been reduced to the floor price, suggesting that the market price of the common stock has been trading at or below this level.

Risks

• Forward-looking statements involve risks and uncertainties, and actual results may differ materially.
• No assurance that Ampligen will be effective in treating viral diseases, cancers, or immune-deficiency disorders, requiring significant additional testing and trials.
• Results from animal models do not necessarily predict human results, and human clinical trials are necessary to prove efficacy.
• Current or planned clinical trials may not be successful, yield favorable data, or may be subject to factors like lack of regulatory approval, study drug, or changes in institutional priorities.
• Clinical trials with preliminary data from small subject numbers may not prove true or yield favorable results in larger studies.
• Future studies may yield findings different from those previously reported.
• Operating in foreign countries carries risks, including potential difficulties in enforcing intellectual property rights.
• Adverse effects on potential foreign operations due to these risks.
• Referral to the Risk Factors section in the latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q for comprehensive risks.

Future Outlook

The company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders. Significant additional testing and trials will be required, and there is no assurance that current or planned clinical trials will be successful or yield favorable data.

Management Comments

• We claim the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
• We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date thereof.

Industry Context

The biotech and pharmaceutical industry is characterized by high-risk, long-term drug development cycles. The company's ongoing efforts with Ampligen reflect the typical challenges of clinical trials, regulatory approvals, and the inherent uncertainties in bringing new treatments to market, where animal model results do not guarantee human efficacy.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Warrant Holders: The exercise price of their warrants has been reduced to $1.439, and the number of outstanding warrants has increased to 5,561,125, potentially making the warrants more "in-the-money" if the stock trades above this floor.
• Common Shareholders: The stock dividend of 1 share for every 1,000 shares outstanding dilutes existing shares slightly, and the low VWAP that triggered the warrant adjustment suggests recent downward pressure on the stock price.

Next Steps

• Continued testing and trials for Ampligen to determine its effectiveness in treating viral diseases, cancers, and immune-deficiency disorders.
• Potential human clinical trials to prove Ampligen's efficacy.

Key Dates

Keywords

AIM ImmunoTech, Warrants, Common Stock, Exercise Price, Stock Dividend, Share Combination Event, VWAP, Floor Price, Ampligen, Biotechnology, SEC Filing, Corporate Governance, Financial Reporting